AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board
MARKHAM, ON, Sept. 17 /PRNewswire-FirstCall/ — AlphaRx Inc. (OTCBB: ALRX) is pleased to announce the appointment of Dr. Donald Low to its Scientific Advisory Board (SAB), effective immediately. With more than 30 years of experience, Dr. Low is recognized world-wide as an authority in the area of emerging infectious diseases.
Dr. Low is currently Head the Division of Microbiology, Department of Laboratory Medicine and Pathobiology at the University of Toronto in Toronto, Ontario. He is also Chief of University Health Network and Mount Sinai Hospital Department of Microbiology, as well as Professor for the Departments of Microbiology and Medicine at the University of Toronto. In addition, Dr. Low is Medical Director of the Public Health Laboratories for the Ontario Ministry of Health and Long-Term Care.
Dr. Low brings with him years of research experience in infectious diseases, particularly in new drug investigation, clinical trials design and implementation. The Scientific Advisory Board (SAB) will be instrumental in implementing AlphaRx’s goal of advancing its lead pharmaceutical product Zysolin(TM) through clinical development.
About Zysolin(TM)
Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx’s Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin – in layman’s term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectable Tobramycin.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
AlphaRx Inc.
CONTACT: Agora Investor Relations Corp., Web: http://www.agoracom.com/(Select “AlphaRx” Forum), E-mail: ALRX@Agoracom.com